GALT

GALECTIN THERAPEUTICS INC

GALECTIN THERAPEUTICS INC (GALT) has 8 SEC Form 4 filings (53 transaction rows) in the rolling window, disclosed by 3 distinct insiders. Most recent filing: Jul 16, 2026.

The most active filer is Chief Medical Officer Jamil Khurram with 5 filings. Insiders have net sold $522K over the trailing 6 months.

  • Industry:Biotechnology
  • CEO:Joel Lewis
  • Employees:15
  • HQ:Norcross, GA, US
  • IPO:2002-09-04

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$2.1M

reported sales (SEC code S)

Unique Insiders

3

in the rolling window

Market Cap

$351.7M

latest known value

Source
Sale$83KJul 16SEC ↗
Shlevin Harold H.First in 7 months
Sale$39KJun 30SEC ↗
Shlevin Harold H.First in 7 months
Sale$112KJun 30SEC ↗
Sale$23KJun 30SEC ↗
Sale$239KJun 30SEC ↗
Sale$24KJun 25SEC ↗
Jamil KhurramFirst filing
Sale$2KMay 28SEC ↗
Shlevin Harold H.First filing
Sale$831KDec 10SEC ↗
Shlevin Harold H.First filing
Sale$105KDec 10SEC ↗
Sale$191KNov 19SEC ↗
Sale$288KNov 19SEC ↗
CALLICUTT JACK WFirst filing
Sale$23KNov 5SEC ↗
CALLICUTT JACK WFirst filing
Sale$174KNov 5SEC ↗

Related companies

GALECTIN THERAPEUTICS INC is in the Healthcare sector.